Table 2. Visual and anatomic characteristics (n=21 eyes).
Baseline following previous ranibizumab/bevacizumab | 24-month post transition to aflibercept | P-valuea | |
---|---|---|---|
Mean BCVA (logMAR) | 0.42±0.31 | 0.42±0.23 | 0.20 |
Mean OCT CFT (microns) | 292.1±83.2 | 283.6±78.6 | 0.40 |
Mean OCT MV (mm3) | 7.9±0.95 | 7.67±0.94 | 0.16 |
Mean treatment interval (days) | 37.0 | 59.3 | 0.01 |
Abbreviations: BCVA, best-corrected visual acuity; CFT, central subfoveal thickness; MV, macular volume.
Paired t-test; data presented as mean±SD.